Search: onr:"swepub:oai:gup.ub.gu.se/254976" >
A Structured Review...
A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) Initiative
- Article/chapterEnglish2017
Publisher, publication year, extent ...
-
Ovid Technologies (Wolters Kluwer Health),2017
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/254976
-
https://gup.ub.gu.se/publication/254976URI
-
https://doi.org/10.1161/circulationaha.117.024469DOI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Peripheral artery disease affects >200 million people worldwide and is associated with significant limb and cardiovascular morbidity and mortality. Limb revascularization is recommended to improve function and quality of life for symptomatic patients with peripheral artery disease with intermittent claudication who have not responded to medical treatment. For patients with critical limb ischemia, the goals of revascularization are to relieve pain, help wound healing, and prevent limb loss. The baseline risk of cardiovascular and limb-related events demonstrated among patients with stable peripheral artery disease is elevated after revascularization and related to atherothrombosis and restenosis. Both of these processes involve platelet activation and the coagulation cascade, forming the basis for the use of antiplatelet and anticoagulant therapies to optimize procedural success and reduce postprocedural cardiovascular risk. Unfortunately, few high-quality, randomized data to support use of these therapies after peripheral artery disease revascularization exist, and much of the rationale for the use of antiplatelet agents after endovascular peripheral revascularization is extrapolated from percutaneous coronary intervention literature. Consequently, guideline recommendations for antithrombotic therapy after lower limb revascularization are inconsistent and not always evidence-based. In this context, the purpose of this structured review is to assess the available randomized data for antithrombotic therapy after peripheral arterial revascularization, with a focus on clinical trial design issues that may affect interpretation of study results, and highlight areas that require further investigation.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Norgren, L.
(author)
-
Ansel, G. M.
(author)
-
Capell, W. H.
(author)
-
Fletcher, J. P.
(author)
-
Fowkes, F. G. R.
(author)
-
Gottsater, A.
(author)
-
Hitos, K.
(author)
-
Jaff, M. R.
(author)
-
Nordanstig, JoakimGothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine(Swepub:gu)xnjoak
(author)
-
Hiatt, W. R.
(author)
-
Göteborgs universitetInstitutionen för medicin, avdelningen för molekylär och klinisk medicin
(creator_code:org_t)
Related titles
-
In:Circulation: Ovid Technologies (Wolters Kluwer Health)135:25, s. 2534-25550009-73221524-4539
Internet link
Find in a library
To the university's database
- By the author/editor
-
Hess, C. N.
-
Norgren, L.
-
Ansel, G. M.
-
Capell, W. H.
-
Fletcher, J. P.
-
Fowkes, F. G. R.
-
show more...
-
Gottsater, A.
-
Hitos, K.
-
Jaff, M. R.
-
Nordanstig, Joak ...
-
Hiatt, W. R.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
Circulation
- By the university
-
University of Gothenburg